Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
J Biotechnol ; 150(3): 417-27, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20888877

ABSTRACT

Widely known for its role in adipogenesis and energy metabolism, PPARγ also plays a role in platelet function. To further understand functions of platelet-derived PPARγ, we produced rabbit polyclonal (PoAbs) and mouse monoclonal (MoAbs) antibodies against PPARγ 14mer/19mer peptide-immunogens. Unexpectedly, our work produced two key findings. First, MoAbs but not PoAbs produced against PPARγ peptide-immunogens displayed antigenic crossreactivity with highly conserved PPARα and PPARß/δ. Similarly, Santa Cruz PoAb sc-7196 was monospecific for PPARγ while MoAb sc-7273 crossreacted with PPARα and PPARß/δ. Second, immunized rabbits and mice exhibited unusual pathology including cachexia, excessive bleeding, and low platelet counts leading to thrombocytopenia. Spleens from immunized mice were fatty, hemorrhagic and friable. Although passive administration of anti-PPARγ PoAbs failed to induce experimental thrombocytopenia, megakaryocytopoiesis was induced 4-8-fold in mouse spleens. Similarly, marrow megakaryocytopoiesis was enhanced 1.8-4-fold in immunized rabbits. These peptide-immunogens are 100% conserved in human, rabbit and mouse; thus, immune-mediated platelet destruction via crossreactivity with platelet-derived PPARγ likely caused bleeding, thrombocytopenia, and compensatory megakaryocytopoiesis. Such overt pathology would cause significant problems for large-scale production of anti-PPARγ PoAbs. Furthermore, a major pitfall associated with MoAb production against closely related molecules is that monoclonicity does not guarantee monospecificity, an issue worth further scientific scrutiny.


Subject(s)
Antibodies/metabolism , Homeostasis/physiology , PPAR gamma/physiology , Peptides/immunology , Thrombocytopenia , Thrombopoiesis , Animals , Antibodies/immunology , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/metabolism , Cachexia , Epitope Mapping , Female , Histocytochemistry , Humans , Intestines/pathology , Liver/pathology , Mice , Mice, Inbred BALB C , Ovary/pathology , PPAR gamma/antagonists & inhibitors , PPAR gamma/chemistry , PPAR gamma/immunology , PPAR gamma/metabolism , Peptides/chemistry , Peptides/metabolism , Protein Isoforms , Rabbits , Spleen/pathology , Thrombocytopenia/pathology , Thrombocytopenia/physiopathology
2.
Arterioscler Thromb Vasc Biol ; 29(11): 1874-82, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19661482

ABSTRACT

OBJECTIVE: Platelets are crucial for hemostasis and are vital regulators of inflammation. Foxp3 is a key transcription factor for T regulatory cell development. Humans with IPEX (immune dysregulation, polyendocrinopathy, enteropathy, x-linked) and the scurfy (Foxp3(sf)) mouse have mutations in the Foxp3 gene that lead to a host of pathologies including autoimmunity and skin diseases. Scurfy mice and some humans with IPEX are also thrombocytopenic. The purpose of this study was to determine whether the absence of functional Foxp3 leads to defects in megakaryocytes and platelets. METHODS AND RESULTS: We discovered that human and mouse megakaryocytes express Foxp3 mRNA and protein. Using shRNA and Foxp3(sf) mice, we demonstrated that Foxp3-deficient mouse and human megakaryocyte progenitors exhibited proliferation defects. Striking platelet abnormalities were observed in both an IPEX patient and Foxp3(sf) mice. Impaired platelet spreading and release of TGF-beta and CD40 ligand (CD40L), and abnormal levels of plasma CD40L were observed in a case of IPEX syndrome. Foxp3(sf) mice were thrombocytopenic and had increased platelet volume and altered serum levels of CD40L, TXB(2), and TGF-beta. CONCLUSIONS: These findings provide compelling new evidence that Foxp3 is needed for proper megakaryopoiesis and plays a role in regulating platelet function including spreading and release.


Subject(s)
Blood Platelets/metabolism , Forkhead Transcription Factors/metabolism , Megakaryocytes/metabolism , Thrombopoiesis/physiology , Animals , Blood Platelets/cytology , Blotting, Western , Cell Proliferation , Cells, Cultured , Flow Cytometry , Forkhead Transcription Factors/genetics , Humans , Male , Megakaryocytes/cytology , Mice , Mice, Inbred C57BL , Mice, Knockout , Probability , RNA, Messenger/analysis , Species Specificity
3.
Blood ; 112(10): 4051-60, 2008 Nov 15.
Article in English | MEDLINE | ID: mdl-18755987

ABSTRACT

Thrombocytopenia is a critical problem that occurs in many hematologic diseases, as well as after cancer therapy and radiation exposure. Platelet transfusion is the most commonly used therapy but has limitations of alloimmunization, availability, and expense. Thus, the development of safe, small, molecules to enhance platelet production would be advantageous for the treatment of thrombocytopenia. Herein, we report that an important lipid mediator and a peroxisome proliferator-activated receptor gamma (PPARgamma) ligand called 15-deoxy-Delta(12,14) prostaglandin J(2) (15d-PGJ(2)), increases Meg-01 maturation and platelet production. 15d-PGJ(2) also promotes platelet formation from culture-derived mouse and human megakaryocytes and accelerates platelet recovery after in vivo radiation-induced bone marrow injury. Interestingly, the platelet-enhancing effects of 15d-PGJ(2) in Meg-01 cells are independent of PPARgamma, but dependent on reactive oxygen species (ROS) accumulation; treatment with antioxidants such as glutathione ethyl ester (GSH-EE); or N-acetylcysteine (NAC) attenuate 15d-PGJ(2)-induced platelet production. Collectively, these data support the concept that megakaryocyte redox status plays an important role in platelet generation and that small electrophilic molecules may have clinical efficacy for improving platelet numbers in thrombocytopenic patients.


Subject(s)
Antineoplastic Agents/pharmacology , Blood Platelets/metabolism , Megakaryocytes/metabolism , Prostaglandin D2/analogs & derivatives , Thrombocytopenia/metabolism , Acetylcysteine/pharmacology , Animals , Antineoplastic Agents/therapeutic use , Antioxidants/pharmacology , Bone Marrow/metabolism , Cell Line , Female , Glutathione/analogs & derivatives , Glutathione/pharmacology , Humans , Male , Mice , PPAR gamma/metabolism , Platelet Transfusion , Prostaglandin D2/pharmacology , Prostaglandin D2/therapeutic use , Radiation Injuries, Experimental/metabolism , Radiation Injuries, Experimental/therapy , Reactive Oxygen Species/metabolism , Thrombocytopenia/therapy
4.
Am J Physiol Lung Cell Mol Physiol ; 292(2): L567-76, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17041012

ABSTRACT

The silent information regulator 2 (Sir2) family of proteins (sirtuins or SIRTs), which belong to class III histone/protein deacetylases, have been implicated in calorie restriction, aging, and inflammation. We hypothesized that cigarette smoke-mediated proinflammatory cytokine release is regulated by SIRT1 by its interaction with NF-kappaB in a monocyte-macrophage cell line (MonoMac6) and in inflammatory cells of rat lungs. Cigarette smoke extract (CSE) exposure to MonoMac6 cells caused dose- and time-dependent decreases in SIRT1 activity and levels, which was concomitant to increased NF-kappaB-dependent proinflammatory mediator release. Similar decrements in SIRT1 were also observed in inflammatory cells in the lungs of rats exposed to cigarette smoke as well as with increased levels of several NF-kappaB-dependent proinflammatory mediators in bronchoalveolar lavage fluid and in lungs. Sirtinol, an inhibitor of SIRT1, augmented, whereas resveratrol, an activator of SIRT1, inhibited CSE-mediated proinflammatory cytokine release. CSE-mediated inhibition of SIRT1 was associated with increased NF-kappaB levels. Furthermore, we showed that SIRT1 interacts with the RelA/p65 subunit of NF-kappaB, which was disrupted by cigarette smoke, leading to increased acetylation RelA/p65 in MonoMac6 cells. Thus our data show that SIRT1 regulates cigarette smoke-mediated proinflammatory mediator release via NF-kappaB, implicating a role of SIRT1 in sustained inflammation and aging of the lungs.


Subject(s)
Aging , Inflammation Mediators/metabolism , Macrophages/metabolism , Sirtuins/metabolism , Smoke/adverse effects , Transcription Factor RelA/metabolism , Acetylation/drug effects , Aging/drug effects , Animals , Benzamides/pharmacology , Bronchoalveolar Lavage Fluid/cytology , Humans , Inflammation , Interleukin-8/metabolism , Lung/drug effects , Lung/pathology , Macrophages/cytology , Macrophages/drug effects , Models, Immunological , Naphthols/pharmacology , Neutrophils/cytology , Neutrophils/drug effects , Rats , Sirtuin 1 , Sirtuins/antagonists & inhibitors , Nicotiana/adverse effects , Tumor Necrosis Factor-alpha/metabolism
5.
Am J Pathol ; 169(4): 1183-93, 2006 Oct.
Article in English | MEDLINE | ID: mdl-17003477

ABSTRACT

The differentiation of preadipocyte fibroblasts to adipocytes is a crucial process to many disease states including obesity, cardiovascular, and autoimmune diseases. In Graves' disease, the orbit of the eye can become severely inflamed and infiltrated with T lymphocytes as part of the autoimmune process. The orbital fibroblasts convert to fat-like cells causing the eye to protrude, which is disfiguring and can lead to blindness. Recently, the transcription factor peroxisome proliferator activated receptor (PPAR)-gamma and its natural (15d-PGJ2) and synthetic (thiazolidinedione-type) PPAR-gamma agonists have been shown to be crucial to the in vitro differentiation of preadipocyte fibroblasts to adipocytes. We show herein several novel findings. First, that activated T lymphocytes from Graves' patients drive the differentiation of PPAR-gamma-expressing orbital fibroblasts to adipocytes. Second, this adipogenic differentiation is blocked by nonselective small molecule cyclooxygenase (Cox)-1/Cox-2 inhibitors and by Cox-2 selective inhibitors. Third, activated, but not naïve, human T cells highly express Cox-2 and synthesize prostaglandin D2 and related prostaglandins that are PPAR-gamma ligands. These provocative new findings provide evidence for how activated T lymphocytes, through production of PPAR-gamma ligands, profoundly influence human fibroblast differentiation to adipocytes. They also suggest the possibility that, in addition to the orbit, T lymphocytes influence the deposition of fat in other tissues.


Subject(s)
Adipocytes/cytology , Adipogenesis , Cell Differentiation , Cyclooxygenase 2/metabolism , Membrane Proteins/metabolism , Orbit/cytology , Prostaglandins/biosynthesis , T-Lymphocytes/enzymology , Coculture Techniques , Fibroblasts/cytology , Fibroblasts/metabolism , Graves Disease/enzymology , Humans , Ligands , Lymphocyte Activation , PPAR gamma/agonists , PPAR gamma/metabolism , Prostaglandin D2/analogs & derivatives , Prostaglandin D2/biosynthesis , Prostaglandin D2/pharmacology , T-Lymphocytes/metabolism
6.
Am J Physiol Lung Cell Mol Physiol ; 291(1): L46-57, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16473865

ABSTRACT

Cigarette smoke-mediated oxidative stress induces an inflammatory response in the lungs by stimulating the release of proinflammatory cytokines. Chromatin remodeling due to histone acetylation and deacetylation is known to play an important role in transcriptional regulation of proinflammatory genes. The aim of this study was to investigate the molecular mechanism(s) of inflammatory responses caused by cigarette smoke extract (CSE) in the human macrophage-like cell line MonoMac6 and whether the treatment of these cells with the antioxidant glutathione (GSH) monoethyl ester, or modulation of the thioredoxin redox system, can attenuate cigarette smoke-mediated IL-8 release. Exposure of MonoMac6 cells to CSE (1% and 2.5%) increased IL-8 and TNF-alpha production vs. control at 24 h and was associated with significant depletion of GSH levels associated with increased reactive oxygen species release in addition to activation of NF-kappaB. Inhibition of IKK ablated the CSE-mediated IL-8 release, suggesting that this process is dependent on the NF-kappaB pathway. CSE also reduced histone deacetylase (HDAC) activity and HDAC1, HDAC2, and HDAC3 protein levels. This was associated with posttranslational modification of HDAC1, HDAC2, and HDAC3 protein by nitrotyrosine and aldehyde-adduct formation. Pretreatment of cells with GSH monoethyl ester, but not thioredoxin/thioredoxin reductase, reversed cigarette smoke-induced reduction in HDAC levels and significantly inhibited IL-8 release. Thus cigarette smoke-induced release of IL-8 is associated with activation of NF-kappaB via IKK and reduction in HDAC levels/activity in macrophages. Moreover, cigarette smoke-mediated proinflammatory events are regulated by the redox status of the cells.


Subject(s)
Histone Deacetylases/metabolism , Interleukin-8/metabolism , Macrophages/immunology , NF-kappa B/metabolism , Smoking/adverse effects , Cell Line, Tumor , Glutathione/analogs & derivatives , Glutathione/metabolism , Glutathione/pharmacology , Humans , I-kappa B Kinase/metabolism , Leukemia, Monocytic, Acute , Macrophages/cytology , Macrophages/enzymology , Oxidants/metabolism , Oxidative Stress/drug effects , Oxidative Stress/immunology , Protein Processing, Post-Translational/immunology , Pulmonary Disease, Chronic Obstructive/immunology , Pulmonary Disease, Chronic Obstructive/metabolism , Signal Transduction/drug effects , Signal Transduction/immunology , Smoking/immunology , Thioredoxin-Disulfide Reductase/pharmacology , Tumor Necrosis Factor-alpha/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...